Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells

Genome Research

Volumn 27, Issue 4, 2017, Pages 533-544

  Cai, Yi ^a   Tsai, Hsing Chen ^b,c   Yen, Ray Whay Chiu ^a   Zhang, Yang W ^a   Kong, Xiangqian ^a   Wang, Wei ^a   Xia, Limin ^a   Baylin, Stephen B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; SHORT HAIRPIN RNA; CCAAT ENHANCER BINDING PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; DNMT1 PROTEIN, HUMAN; UHRF1 PROTEIN, HUMAN;

ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA METHYLATION; ENHANCER REGION; GENE EXPRESSION; GENE SILENCING; HCT 116 CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TARGETING; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM;

CCAAT-ENHANCER-BINDING PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HCT116 CELLS; HUMANS; PROMOTER REGIONS, GENETIC;

EID: 85017556888     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.208108.116     Document Type: Article

References (66)

1. Ahuja N, Easwaran H, Baylin SB. 2014. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124: 56-63.
2. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, et al. 2012. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336: 736-739.
3. Akiyama Y, Watkins N, Suzuki H, JairKW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, et al. 2003. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 23: 8429-8439.
4. Azad N, Zahnow CA, Rudin CM, Baylin SB. 2013. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 10: 256-266.
5. Bachman KE, Rountree MR, Baylin SB. 2001. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem 276: 32282-32287.
6. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B. 2003. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3: 89-95.
7. Baubec T, Colombo DF, Wirbelauer C, Schmidt J, Burger L, Krebs AR, Akalin A, Schübeler D. 2015. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature 520: 243-247.
8. Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11: 726-734.
9. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CP, van Dijk CM, Tollenaar RA, et al. 2012. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-Associated domains. Nat Genet 44: 40-46.
10. Blattler A, Yao L, Witt H, Guo Y, Nicolet CM, Berman BP, Farnham PJ. 2014. Global loss of DNA methylation uncovers intronic enhancers in genes showing expression changes. Genome Biol 15: 469.
11. Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE. 2007. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317: 1760-1764.
12. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
13. Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, Stankova M, Hrabakova P, Pegova K, Zizkova H, et al. 2012. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma 59: 168-174.
14. Challen GA, Sun D, Mayle A, Jeong M, Luo M, Rodriguez B, Mallaney C, Celik H, Yang L, Xia Z, et al. 2014. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15: 350-364.
15. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. 2003. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 23: 5594-5605.
16. Chen T, Hevi S, Gay F, Tsujimoto N, He T, Zhang B, Ueda Y, Li E. 2007. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 39: 391-396.
17. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. 2015. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162: 974-986.
18. Clermont PL, Parolia A, Liu HH, Helgason CD. 2016. DNA methylation at enhancer regions: novel avenues for epigenetic biomarker development. Front Biosci (Landmark Ed) 21: 430-446.
19. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, et al. 2010. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci 107: 21931-21936.
20. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lübbert M. 2002. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′- deoxycytidine (decitabine) treatment. Blood 100: 2957-2964.
21. Easwaran H, Tsai HC, Baylin SB. 2014. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54: 716-727.
22. Egger G, Jeong S, Escobar SG, Cortez CC, Li TW, Saito Y, Yoo CB, Jones PA, Liang G. 2006. Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci 103: 14080-14085.
23. The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
24. Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
25. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer- Rachamimov AO, Suvà ML, Bernstein BE. 2016. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529: 110-114.
26. Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi B, Hou P. 2013. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer 13: 462.
27. Grimmer MR, Farnham PJ. 2014. Can genome engineering be used to target cancer-Associated enhancers? Epigenomics 6: 493-501.
28. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530.
29. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, et al. 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 22: 246-258.
30. Issa JP. 2005. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2(Suppl 1): S24-S29.
31. Issa JP, Roboz G, Rizzieri D, Jabbour E, StockW, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al. 2015. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16: 1099-1110.
32. Kao CS, Badve SS, Ulbright TM. 2014. The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma. Histopathology 65: 35-44.
33. Kelly TK, De Carvalho DD, Jones PA. 2010. Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078.
34. Kron KJ, Bailey SD, Lupien M. 2014. Enhancer alterations in cancer: A source for a cell identity crisis. Genome Med 6: 77.
35. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al. 2010. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433.
36. Li Z, Dai H, Martos SN, Xu B, Gao Y, Li T, Zhu G, Schones DE, Wang Z. 2015. Distinct roles of DNMT1-dependent and DNMT1-independent methylation patterns in the genome of mouse embryonic stem cells. Genome Biol 16: 115.
37. Liao J, Karnik R, Gu H, Ziller MJ, Clement K, Tsankov AM, Akopian V, Gifford CA, Donaghey J, Galonska C, et al. 2015. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat Genet 47: 469-478.
38. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al. 2009. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462: 315-322.
39. Michael AK, Harvey SL, Sammons PJ, Anderson AP, Kopalle HM, Banham AH, Partch CL. 2015. Cancer/testis antigen PASD1 silences the circadian clock. Mol Cell 58: 743-754.
40. Myöhänen SK, Baylin SB, Herman JG. 1998. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res 58: 591-593.
41. Qin W, Leonhardt H, Pichler G. 2011. Regulation of DNA methyltransferase 1 by interactions and modifications. Nucleus 2: 392-402.
42. Rhee I, JairKW, Yen RW, Lengauer C, Herman JG, KinzlerKW, Vogelstein B, Baylin SB, Schuebel KE. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404: 1003-1007.
43. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.
44. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, et al. 2015. Integrative analysis of 111 reference human epigenomes. Nature 518: 317-330.
45. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33: 61-65.
46. Rothbart SB, Dickson BM, Ong MS, Krajewski K, Houliston S, Kireev DB, Arrowsmith CH, Strahl BD. 2013. Multivalent histone engagement by the linked tandem Tudor and PHD domains of UHRF1 is required for the epigenetic inheritance of DNA methylation. Genes Dev 27: 1288-1298.
47. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. 2015. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162: 961-973.
48. Rountree MR, Bachman KE, Baylin SB. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277.
49. Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, Meyer MR, Erdmann-Gilmore P, Townsend RR, Wilson RK, et al. 2014. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-Type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25: 442-454.
50. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, et al. 2007. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709-1723.
51. Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, et al. 2007. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450: 908-912.
52. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G. 2011. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet 7: E1001286.
53. Shen H, Laird PW. 2013. Interplay between the cancer genome and epigenome. Cell 153: 38-55.
54. Smith E, Shilatifard A. 2014. Enhancer biology and enhanceropathies. Nat Struct Mol Biol 21: 210-219.
55. Spada F, Haemmer A, Kuch D, Rothbauer U, Schermelleh L, Kremmer E, Carell T, Längst G, Leonhardt H. 2007. DNMT1 but not its interaction with the replication machinery is required for maintenance of DNA methylation in human cells. J Cell Biol 176: 565-571.
56. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, et al. 2004. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422.
57. Taguchi A, Taylor AD, Rodriguez J, Celiktas M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, et al. 2014. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. Cancer Res 74: 4694-4705.
58. Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB, Schuebel KE. 2004. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 36: 582-584.
59. Tsai HC, Baylin SB. 2011. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21: 502-517.
60. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. 2012. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
61. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, Cross MK, Williams BA, Stamatoyannopoulos JA, Crawford GE, et al. 2013. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res 23: 555-567.
62. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA. 2004. Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2: 62-72.
63. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al. 2011. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43: 309-315.
64. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. 2014. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26: 577-590.
65. Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, et al. 2008. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 68: 2764-2772.
66. Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LT, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE, et al. 2013. Charting a dynamic DNA methylation landscape of the human genome. Nature 500: 477-481.